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Abstract 
Cancer stem cells (CSC) represent a small subpopulation of cells in malignant tumors that possess the unique ability 
to self-renew, differentiate and resist chemo- and radiotherapy. These cells have been postulated to be the basis for 
some of the difficulties in treating cancer, and therefore, numerous approaches have been developed to specifically 
target and eliminate CSC in diverse types of cancer, including breast cancer. Spontaneously occurring mammary 
tumors in canines share clinical and molecular similarities with the human counterpart, making the dog a potentially 
powerful model for the study of human breast cancer and clinical trials. Studies focused on canine mammary CSC 
might therefore enhance our understanding of the biology and possible treatment of the disease in both dogs and 
humans. In this review, we discuss various approaches currently in use to isolate and characterize canine mammary 
CSC.
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Background
Canine mammary tumors (CMT) remain some of 
the most common neoplasms affecting female dogs. 
Approximately 200–250 new diagnoses of CMT per 
100,000 bitches are reported annually [1, 2], and of these 
cases, ~50% are malignant [3, 4]. Surgical removal of the 
tumor is a standard treatment for CMT, but in many 
cases, the procedure alone is ineffective due to existing 
micro-metastases [3]. Moreover, lack of effective chemo- 
and radiotherapy following mastectomy excludes possi-
ble alternative treatment strategies.
Recently, it has been hypothesized that a small sub-
population of cells, cancer stem cells (CSC), underlies 
tumor initiation, progression and metastasis. CSC are 
thought to share similar properties with normal stem 
cells, such as the ability to self-renew and differenti-
ate into various cell types. High expression of adenosine 
triphosphate (ATP)-binding cassette transporters, quies-
cence and specific DNA repair abilities also make them 
remarkably drug resistant [5]. Therefore, understand-
ing the biology of CSC and critical pathways involved in 
their maintenance might lead us to the discovery of novel 
compounds for breast cancer therapy.
Interestingly, CMT shares many clinical and molecular 
similarities with human breast cancer. Epidemiology and 
tumor behaviour follow the same pattern as in humans, 
rendering spontaneously occurring CMT an interesting 
model for breast cancer preclinical studies. Thus, close 
cooperation between human and veterinary medicine in 
breast cancer studies is likely to be of mutual benefit for 
treatment of the disease in both humans and dogs.
This review summarizes current knowledge regard-
ing canine mammary CSC. Various techniques used for 
CSC isolation, the signaling pathways involved in tumor 
development, and studies regarding drug resistance and 
targeted treatment are presented. In addition, current 
challenges and future perspectives in the study of CMT 
are discussed.
Search strategy
A literature search was performed in PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) using the terms “canine 
mammary tumor” OR “canine neoplasms” AND “can-
cer stem cells” OR “canine mammary cancer stem cells”. 
Only papers written in English and published within the 
last 25 years through November 2016 were included. All 
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articles based on cancer stem-like cells isolated from 
tumor samples and canine mammary tumor cell lines 
were incorporated. Studies employing immunohisto-
chemistry as a method for the identification of cancer 
stem-like cells in  situ were evaluated, and the most rel-
evant to our review were selected. An additional resource 
was our own data from the isolation and identification of 
canine cancer stem-like cells [6, 7].
Canine model for breast cancer studies
Breast cancer is the second leading cause of death in 
women worldwide [8]. The International Agency for 
Research on Cancer (IARC) estimated in 2012 that 
approximately 1.67 million women were diagnosed with 
breast cancer globally, and 522,000 died from the disease 
or related complications. At present, a murine model 
with inducible or implanted mammary tumors is used 
in the majority of human breast cancer studies. Despite 
the broad capability to investigate complex mechanisms 
of cancer pathways, tumor progression and therapeutic 
agents, genetically engineered mice possess limitations 
in modeling human cancer. Alterations in the immune 
system of certain mouse strains, inbreeding and homo-
geneity of experimental cells implanted into mice all 
lead to a limited picture of tumor biology. In this regard, 
the dog might be a unique alternative for breast can-
cer research for a number of reasons. First, the disease 
in dogs is pathologically similar to that in humans, and 
importantly, exhibits the heterogeneity that is observed 
in human tumors [9]. Second, the dog is one of the few 
species in which mammary gland neoplasms occur spon-
taneously with almost 3 times the incidence in humans 
[10]. The highest incidence occurs in intact, older bitches 
in the age range of 8–12  years [11]. Third, the clinical 
course and tumor progression of CMT is comparable to 
breast cancer in women. In both, for example, larger size 
and metastasis detected in adjacent lymph nodes or dis-
tant organs are correlated with higher tumor grade and 
poorer prognosis [12]. Fourth, shorter overall lifespan 
than human and larger size compared to mouse enables 
the possibility of monitoring tumor progression and 
treatment outcomes in a shorter period of time. Fifth, 
close similarity to the human genome and comparable 
kinetics regarding drug metabolism indicates that the 
canine might be an invaluable model bridging clinical 
trials between mouse and human (Fig.  1). Finally, envi-
ronmental factors, including diet, lifestyle, and UV and 
chemical exposure, are similar between dogs and humans 
[9].
Cancer stem cells
A solid tumor is a heterogeneous mass made up of a vari-
ety of cell types, including cancer cells, cells in the tumor 
microenvironment and the extracellular matrix. CSC 
make up a small subpopulation of the cancer cells that 
are thought to play a major role in tumor initiation and 
progression. Unique properties of the CSC, such as self-
renewal, differentiation and drug resistance, determine 
both long-term survival as well as the ability to escape 
chemotherapy.
Although the initial evidence that cancer might arise 
from a population of stem-like cells dates as far back as 
the nineteenth century, improved technology in basic 
cancer research enabled comprehensive studies in this 
field [13]. The development of flow cytometry together 
with discovery of cell surface markers and the increased 
Fig. 1 The canine model provides an invaluable model bridging murine in vivo studies and clinical trials to the study and drug development for 
human breast cancer
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availability of xenograft mouse models for human can-
cer have enabled the isolation and characterization of 
human CSC. A study conducted by Bonnet and Dick in 
1997 was the first to show that within a cancer only a 
certain population of cells possessed the unique poten-
tial for self-renewal [14]. They demonstrated that only 
the CD34+CD38− fraction of cells isolated from human 
acute myeloid leukemia had the ability to initiate hemat-
opoietic malignancy in non-obese diabetic/severe com-
bined immunodeficiency (NOD/SCID) mice during 
serial transplantations. Interestingly, because of the pres-
ence of the same surface markers on normal stem cells, 
the authors proposed that CSC might originate from 
normal primitive cells rather than committed progenitor 
cells. Six years later, Al-Hajj et al. [15] identified cells with 
stem cell-like properties in solid tumors. Using the com-
bination of anti-CD24, anti-CD44 and anti-epithelial-
specific antigen (ESA) antibodies, the authors dissociated 
nine primary or metastatic human breast cancer sam-
ples. The cells were sorted, and 10 serial dilutions were 
injected into the mammary gland of NOD/SCID mice. 
This study revealed the explicit tumorigenic potential of 
selected ESA+CD44+CD24−/low Lineage− cells. As few 
as only 100 cells were able to initiate tumor growth. Fur-
thermore, intra tumor heterogeneity was present in the 
xenografts, paralleling the cellular diversity observed in 
the primary counterparts. Thus, CSC not only self-renew 
but also differentiate into phenol typically diverse cells of 
a particular tumor. To date, stem-like cancer cells have 
been identified in numerous solid tumors including lung, 
prostate, brain, melanoma and ovarian cancer [16–19].
Metastasis, the development of secondary tumors in 
adjacent or distant organs, is estimated to be responsi-
ble for 90% of cancer related deaths [20]. It is believed 
to take place in part through the corruption of a normal 
cellular process, the epithelial-mesenchymal transition 
(EMT), which is observed in normal tissue development 
and wound healing. Reversible transformation of a polar-
ized epithelial cell into a motile mesenchymal type ena-
bles cells to migrate to distant regions, invade tissues and 
generate metastases. Cells undergoing EMT are charac-
terized by a reduced expression of E-cadherin-mediated 
intercellular junctions and keratin rich intermediate fila-
ments with a concurrent increase in mesenchymal mark-
ers including vimentin and fibronectin. Recently, several 
studies suggested that there is a link between CSC and 
EMT. For instance, a study by Mani et  al. [21] revealed 
that induction of the EMT program through SNAIL, 
TWIST or TGF-β1 in immortalized human mammary 
epithelial cells led to the generation of CD44+/CD24− 
cells with stemness properties.
Treatment regimens for human breast cancer today 
often include chemo- and radiotherapy. However, despite 
these aggressive approaches, many patients experience 
tumor recurrence possibly due to the presence of dor-
mant cancer cells [22]. It has been hypothesized that CSC 
with their multiple defense mechanisms largely make up 
this population of tumor cells. Chemotherapy is generally 
most effective against rapidly proliferating cancer cells; 
thus, the low proliferation rate and increased number of 
ATP-driven efflux transporters allow stem-like cells to 
escape the cytotoxic effects of multiple compounds [5]. 
Moreover, the over expression of anti-apoptotic pro-
teins, such as B-cell lymphoma 2 (BCL2), and increased 
resistance to DNA damage make them highly resistant to 
radiotherapy [23]. Failure of chemo- and radiotherapy in 
breast cancer treatment has stimulated research for novel 
compounds that might selectively target those remaining 
CSC.
Isolation of canine mammary cancer stem cells
The discovery of CSC in human breast cancer triggered 
investigation of a similar subpopulation in canine mam-
mary tumors. Based on their characteristic features, 
namely, sphere-forming ability under non-adherent con-
ditions, expression of specific surface markers and high 
expression of ATP-binding cassette (ABC) transporters, 
several methods have been proposed for CSC isolation 
(Fig. 2).
Somatic mammalian cells have limited replicative 
potential and undergo cell senescence. Stem cells dif-
fer in that they possess the unique ability to self-renew 
and to perpetuate their pool throughout the life span of 
an organism. In cancer, CSC exhibit these same prop-
erties driving tumor progression and recurrence. Thus 
methods to enrich for more undifferentiated cell types 
from normal mammary gland tissue, such as the system 
developed by Dontu et al. [24], have been important for 
the functional and molecular characterization of CSC. 
These authors generated more favorable conditions for 
the proliferation of progenitor cells by culturing cells dis-
sociated from tissue on low attachment plates in serum-
free medium supplemented with B27, epidermal growth 
factor (EGF), basic fibroblast growth factor (bFGF) and 
heparin. More cells within floating spherical colonies 
expressed a high level of ABC transporters compared to 
the parental cell line (27 vs 1%, non adherent vs adher-
ent culture, respectively). Moreover, only cells within the 
floating spheres were able to regenerate colonies and pos-
sessed multi lineage differentiation potential.
Using this method, Cocola et al. [25] isolated the first 
canine mammary CSC in 2009. Serially dissociated 
spheroids obtained from eight CMT samples were able 
to regenerate for up to 5 passages and displayed similar 
morphology to mammospheres obtained from normal 
tissue. In a 3D assay in  vitro, the canine CSC cultured 
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on collagen gels generated branching structures remi-
niscent of primitive tubes of the mammary gland, and 
when implanted into the fat pads of NOD/SCID mice, 
induced tumor growth. The regeneration potential as 
well as the number of spheroids varied in subsequent 
studies [25–33]. Cells isolated from the REM134 canine 
mammary carcinoma cell line formed spheres 16 times 
in long-term serial passaging. These cells were cultured 
under analogous conditions but were additionally sup-
plemented with progesterone, putrescine, sodium sel-
enite, transferrin and insulin [29]. Differences in sphere 
culturing media however have also been shown to influ-
ence the regeneration potential of CSC from CMT. The 
results of these experiments revealed that in contrast to 
stem cells isolated from normal mammary gland tissue, 
self-renewal of CSC was repressed by increased concen-
trations of EGF and FGF2 rather than promoted [33]. In 
another study, cells obtained from four canine mammary 
gland adenoma cell lines (1  ×  104) formed between 45 
and 273 spheres demonstrating the existence of different 
percentages of progenitor cells among samples [27].
The self-renewing, sphere culturing system is a useful 
and easy method for the isolation of CSC; however, some 
limitations do exist. First, the in vitro environment may 
not fully reflect in  vivo conditions and may lead to the 
selection of a specific group of cells that might vary from 
putative CSC. Second, calculations for sphere formation 
might be sometimes highly inaccurate, as so-called larger 
spheres are often the result of the aggregation of smaller 
spheres [34]. Finally, technical difficulties in obtaining 
single-cell suspensions might lead to biases and chimer-
ism in the formation of spheres.
One of the most common methods currently used to 
isolate CSC from human breast cancer samples is flow 
cytometry. Based on the expression of specific cell sur-
face markers or functional properties, CSC can be easily 
and quickly identified. Using multiple parameters simul-
taneously, flow cytometry enables the isolation of this 
very rare subpopulation of cells depending on set criteria. 
Human breast CSC have been previously characterized 
as CD44+/CD24−/low [15]. Detection of CD44+/CD24−/
low cells has also been reported in CMT [27, 30, 35]. A 
study by Michishita et al. [27] demonstrated that 85% of 
cells were CD44+/CD24−/low in spheres derived from a 
canine mammary adenocarcinoma cell line. Surprisingly, 
the authors also observed that 45.3–91.7% of cells were 
CD44+/CD24−/low in the four parental cell lines analyzed. 
Such high levels of CD44 positive cells might however 
be associated with proliferation status rather than stem 
cell phenotype as the proportion of cells in G0/G1 that 
are CD44−/low has been shown to be higher than in G2/M 
where the majority are CD44+ [36]. Therefore, isolation 
of CSCs should be performed with a combination of cell 
surface markers.
Ferletta et  al. [30] detected canine mammary CSC 
using the marker stem cell antigen (Sca-1; also known as 
mouse mammary progenitor cell marker) and additional 
antibodies against CD10, CD34, CD44, CD24 and CD49f 
surface markers. In these experiments, the Sca-1+ side 
population from the atypical benign mixed mammary 
tumor line CMT-U229 expressed a CD10low/CD34+/
CD44+/CD24low and CD49f+ antigenic profile. Moreover, 
CD133+ cells sorted from the same Sca-1+ side popula-
tion formed spheroids on low-attachment plates. These 
observations suggested that CD133 and Sca-1 might be 
relevant markers for canine mammary CSC isolation. 
Data from our own studies corroborate these results 
[6]. The Sca-1+ cells isolated from three CMT cell lines 
(CMT-U27, CMT-U309 and P114) formed colonies with 
an undifferentiated morphology and expressed CD44 
and epithelial cell adhesion molecule (EpCAM) genes at 
significantly higher levels. However, in contrast to the 
results of Michishita et  al. [27], only between 0.2 and 
1.2% of cells in these canine mammary neoplastic cell 
Fig. 2 Methods used for the identification and isolation of canine 
mammary cancer stem cells
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lines were characterized with progenitor features and a 
Sca-1+ phenotype.
Immunohistochemistry (IHC) is a second method used 
for the identification and quantification of CSC within 
tumor specimens. A few groups have presented prom-
ising results using this technique [28, 37–40]. In a large 
study conducted by Magalhaes et al. [39], 130 CMT sam-
ples, including benign, malignant and lymph node metas-
tases, were analyzed for CD44 and CD24 expression. 
The CD44+/CD24− phenotype, which is characteristic 
of CSC, was detected more frequently in higher-grade 
tumors and lymph node metastases, while the CD24+ 
phenotype was identified more frequently in lower 
grade samples (grade I) compared to the other patholo-
gies. Similar results were also demonstrated by other 
groups concluding that a higher frequency of CD44+/
CD24− cells is associated with poorer prognosis [37–39]. 
However, results might be often underestimated due to 
non-homogenous expression of CD44 within tissue, 
uneven localization of putative cells and difficulties with 
serial sectioning of samples [41].
Based on current knowledge, there is no single method 
for CSC isolation that is necessarily superior to others. 
The choice of sample type as well as isolation technique 
have certain limitations that should be considered when 
analyzing data. Optimization of the protocol in the future 
might therefore be beneficial in order to more clearly 
define a set of conditions that will lead to consistent and 
comparable results.
Functional characterization of canine mammary 
cancer stem cells
Several groups have analyzed the effect of chemo- and 
radiotherapy on isolated canine mammary CSC. Doxoru-
bicin is a widely used anti-tumor agent that causes DNA 
damage and inhibits cell proliferation. Spheres isolated 
from the canine mammary carcinoma cell line REM134 
cultured with increasing concentrations of doxorubicin 
exhibited higher resistance compared to the parental, 
adherent cells [29]. The cytotoxic effect was almost two-
fold less in these cells. The doses 0.001, 0.01 and 0.05 μM 
left 80, 60 and 30% viable cells, respectively. The same 
cells were resistant to radiation doses of 1–5  Gy and 
exhibited a reduced loss of colony formation ability. 
Increased resistance to doxorubicin and no response to 
paclitaxel treatment were also observed by three other 
groups [27, 31, 35]. Barbieri et  al. [31] did not observe 
any reduction in cell viability, even at the highest concen-
trations (5–10  µM) of the drugs. Discordance between 
results obtained using cell lines and spheres derived from 
tumor samples might be explained by possible different 
gene expressions and cellular properties that occur dur-
ing the process of immortalization [24].
Recently, the effect of three alternative drugs has 
been investigated in the treatment of canine mammary 
tumors. In one study, the anti-diabetic drug metformin 
was shown to specifically inhibit the viability of CSC [31]. 
The IC50 concentration after treatment for 48  h varied 
between samples, resulting in a mean value of ~10 mM. 
In an in  vivo study in NOD/SCID mice, a 62% reduc-
tion in tumor growth was observed in animals receiv-
ing metformin in the drinking water. In culture, only 2% 
of cells dissociated from tumor samples obtained from 
treated animals were able to form spheres compared to 
13% of cells derived from the untreated group. The sig-
nificantly lower clonogenic potential of CSC observed in 
the ex  vivo assay, and the high safety of the drug make 
metformin a promising agent for combined anti-tumor 
therapy [31].
In a second study, simvastatin, a cholesterol-decreasing 
therapeutic used for the prevention of myocardial infarc-
tion, was tested as a potential agent to target CSC [35]. 
Although the drug is known to competitively inhibit 
3-hydroxy-3-methylglutaryl coenzyme A reductase 
which is involved in cholesterol synthesis, it also reduces 
expression of CD44, a CSC surface marker. The effect of 
simvastatin on sphere forming capacity was therefore 
investigated in the canine mammary cancer cell line, 
CF41 Mg, which is enriched for CD44+/CD24−/low cells. 
The number and size of colonies generated in the pres-
ence of the drug was significantly decreased in a dose-
dependent manner. At the molecular level, simvastatin 
led to the reduction of β-catenin in the plasma mem-
brane of cells within spheres and activation of caspase 
3/7 which increased DNA fragmentation in CSC. More-
over, spheres were more sensitive to combination treat-
ment with doxorubicin compared to spheres treated with 
10 µM simvastatin alone [35].
In a third potential therapeutic strategy, melatonin, 
a hormone synthesized by the pineal gland, was shown 
to suppress properties of EMT in CSC. Under treat-
ment with the hormone (1  mM), the expression levels 
of OCT4, N-cadherin and vimentin were significantly 
decreased in CSC isolated from the cell line CMT-U229 
whereas E-cadherin levels were increased. Migration 
and invasion potential of treated cells was also found to 
be reduced, by 40% compared to controls, indicating a 
potential anti-metastatic role for melatonin in CMT [42].
According to Skidan and Steininger [43], anti-CSC 
drugs can be divided into three main categories: chemical 
compounds, small molecules targeting CSC and thera-
peutic biological agents including microRNA (miRNA) 
based drugs. A family of endogenous, non-coding RNAs 
(ncRNA) regulates  ~30% of genes, and altered expres-
sion of miRNA has been associated with cancer develop-
ment [44, 45]. Our group was the first to study miRNA 
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expression in canine CSC isolated from three different 
CMT cell lines [6]. Comparison of miRNA profiles using 
a custom-designed canine miRNA microarray revealed 
significant deregulation of 33 miRNAs in CSC relative to 
differentiated tumor cells. Interestingly, genes targeted 
by the down regulated miRNAs were mostly involved in 
the TGF-β signaling pathway. Similarly, Pang et  al. [29] 
observed that REM134 cells treated with TGF-β led to 
enrichment in the number of sphere-derived cells and 
induced EMT. Therefore, it is possible that regulation of 
the expression of some miRNAs might control EMT and 
deplete the CSC subpopulation.
It has also been recently demonstrated that non-neo-
plastic cell types within the tumor microenvironment 
influence biological properties of CSC isolated from 
CMT [7]. Tumor-associated macrophages (TAMs), the 
most abundant population of immune cells infiltrating 
solid tumors, have been shown to promote over expres-
sion of the monocyte chemo attractant CCL2 in CSC, 
which led to enhanced TAM infiltration [46]. Moreover, 
co-culturing with TAMs yielded CSC with higher inva-
sive potential and elevated pro-angiogenic properties. 
These results corroborate previous findings associating 
TAMs with tumor progression and metastasis in human 
breast cancer [47, 48].
Conclusions and perspectives
Studies performed in recent decades indicate that the 
mechanism of tumor initiation, progression and recur-
rence might be driven by rare subpopulation of cells 
called cancer stem cells. These cells possess the unique 
ability to self-renew and differentiate into a variety of cell 
types. While CSC have been previously characterized in 
numerous human cancers, they have only recently been 
identified in canine neoplasms, including mammary 
tumors. Interestingly, studies have demonstrated that 
canine mammary CSC not only express similar surface 
markers to human CSC but are also resistant to chemo- 
and radiotherapy. These results highlight the value of 
comparative oncology and the possible utility of the 
canine model in breast cancer research.
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